-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)-
-Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV) platform-
Read more at globenewswire.com